Besifloxacin HCl Ophthalmic In situ Gel: Design, Optimization, In vitro and Ex vivo Investigation-Reference-Cited by-同舟云学术

Besifloxacin HCl Ophthalmic In situ Gel: Design, Optimization, In vitro and Ex vivo Investigation

Published:2024-05-15 Issue: Volume: Page:2035-2039
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Desai Aparna¹,Pagariya Ashish²,Rathod Monika¹,Kayande Kalyani³,Chhajed Mahavir⁴,Deokar Rushali⁵,Rai Sudhish⁶

Affiliation:

1. Department of Pharmacognosy, Bhartiya Education Society’s Institute of Pharmacy, Velshet (Nagothane), Dist: Raigad.

2. Department of Pharmacognosy, Bhartiya Education Society’s Institute of Pharmacy, Velshet (Nagothane), Dist: Raigad.

3. Department of Pharmaceutics, Sinhgad Institute of Pharmacy, Narhe, Pune, Maharashtra, India 411041.

4. Vikrant Institute of Pharmacy and Science, Indore.

5. Department of Pharmaceutics, Jaihind College of Pharmacy, Junnar, Pune.

6. Jagrani Devi Pharmacy College, Baradwar, Shakti.

Abstract

The present work aimed to formulate and evaluate Besifloxacin Hydrochloride (HCl) ophthalmic in situ gel for conjunctivitis, based on temperature triggered gelation system to increase ocular residence time, bioavailability and patient compliance. Different formulations were prepared by using Poloxamer 407 and Poloxamer 188 as temperature sensitive as well as mucoadhesive polymers. Design expert software version 11 was used to optimized the formula. Optimized batch having Poloxamer 407 (24.80% w/v) and Poloxamer 188 (14.53% w/v) was evaluated for visual appearance, clarity, gelation temperature, gelling capacity, rheological property, ex vivo, in vitro release and accelerated stability studies. Histopathological study was carried out using Goat cornea and revealed no change in histopathology of the tissues. Formulation was found to be effective against the Escherichia coli and Staphylococcus aureus. Cumulative % drug release of Besifloxacin HCl ophthalmic in situ gel after 8 hours was found to be 96.47 %.

Publisher

A and V Publications

Reference12 articles.

1. A. Hugo, S. Maria, Lobao and L. Jose, In situ gelling system: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov. Today. 2014: 1-13, 10.1016/j.drudis.2013.10.001.

2. Anil G, Rama A, Thirupathi G, Ramesh B. Topical ophthalmic in situ gels for ocular delivery: A recent Update. Saudi J. Med. Pharm. Sci. 2017; 3(7B): 804-807.

3. L. Li, D. Guo, Guo J, Song J, Wu Q, Liu D, Bia H, Xi. Thermosensitive in-situ forming gels for ophthalmic delivery of tea polyphenols. J. Drug Delivery Sci. Technol. 2018; 46: 243–250, 10.1016/j.jddst.2018.05.019.

4. Qian Y, Wang F, Li R, Zhang Q, and Xu Q. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug. Dev. Ind. Pharm. 2010; 36(11): 1340–1347, 10.3109/03639041003801893.

5. Sharadha M, Gowda D, Vishal G, and Bhavya M. Fabrication, Characterization and Evaluation of In Situ Gel for the Treatment of Conjunctivitis. J. Pharm. Sci. Res. 2018; 10(5): 1220-1222.